Oral andro-related prohormone supplementation: Do the potential risks outweigh the benefits?

被引:16
作者
Broeder, CE [1 ]
机构
[1] E Tennessee State Univ, James H Quillen Coll Med, Johnson City, TN 37614 USA
来源
CANADIAN JOURNAL OF APPLIED PHYSIOLOGY-REVUE CANADIENNE DE PHYSIOLOGIE APPLIQUEE | 2003年 / 28卷 / 01期
关键词
resistance exercise; androstenedione; androstenediol; anti-aging;
D O I
10.1139/h03-009
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Androstenedione, 4-androstenediol, 5-androstenediol, 19-norandrostenediol and 19-norandrostenedione are commonly referred to as "Andro" prohormones. Over the last few years, supplementation using these prohormones has been aggressively marketed to the general public. Supplement manufacturers often claim that Andro use improves serum testosterone concentrations, increases muscular strength and muscle mass, helps to reduce body fatness, enhances mood, and improves sexual performance. However to date, most studies contradict these claims. In contrast, several studies using oral Andro related prohormones show that Andro use can abnormally elevate estrogen related hormones as well as alterations in hormonal markers (i.e., abnormal elevations in serum estrogen) thought to increase a person's risk for developing prostate or pancreatic cancers. In addition, most studies also indicate that significant declines in high-density lipoproteins occur leading to an increased cardiovascular disease risk. Thus, to date, the current research base suggests that Andro prohormone use does not support manufacturer claims. But it does suggest there should be strong concerns regarding long-term oral Andro prohormone use, especially regarding its effects on blood lipids and estrogen hormone profiles.
引用
收藏
页码:102 / 116
页数:15
相关论文
共 49 条
[31]   Age-related changes in male gonadal function - Implications for therapy [J].
Maas, D ;
Jochen, A ;
Lalande, B .
DRUGS & AGING, 1997, 11 (01) :45-60
[32]   IN VIVO CONVERSION OF DEHYDROEPIANDROSTERONE AND ANDROSTENEDIONE TO TESTOSTERONE IN HUMAN [J].
MAHESH, VB ;
GREENBLATT, RB .
ACTA ENDOCRINOLOGICA, 1962, 41 (03) :400-&
[33]  
MATSUMINE H, 1986, J CLIN ENDOCR METAB, V63, P717, DOI 10.1210/jcem-63-3-717
[34]   GONADAL PITUITARY-HORMONE LEVELS IN GYNECOMASTIA [J].
MCFADYEN, IJ ;
BOLTON, AE ;
CAMERON, EHD ;
HUNTER, WM ;
RAAB, G ;
FORREST, APM .
CLINICAL ENDOCRINOLOGY, 1980, 13 (01) :77-86
[35]  
MILLER LE, 2000, EFFECTS ORAL ANDROST, P129
[36]  
O'Gara T, 2000, JAMA-J AM MED ASSOC, V283, P741
[37]  
Orth DN, 1998, WILLIAMS TXB ENDOCRI, P517
[38]   Androgens: Basic biology and clinical implication [J].
Orwoll, ES .
CALCIFIED TISSUE INTERNATIONAL, 2001, 69 (04) :185-188
[39]  
PETERSON GE, 1984, PHYSICIAN SPORTSMED, V252, P507
[40]  
Quindry J., 2000, Medicine and Science in Sports and Exercise, V32, pS122